Latent profiles of self-management behavior identified in Chinese ulcerative colitis patients.
Chinese ulcerative colitis patients show varied self-management behaviors linked to social support and mood
This cross-sectional study of 415 Chinese patients with ulcerative colitis identified three self-management behavior profiles. The Emotion-A…
Chinese ulcerative colitis patients with strong social support and fewer mood issues actively manage their daily lives better than others.
Cross-sectional data suggest IgG glycans discriminate inflammatory bowel disease from controls.
A Simple Blood Test May Spot Crohn's and Colitis Early
This cross-sectional study analyzed 1,367 plasma samples from individuals with Crohn's disease or ulcerative colitis, healthy controls, and …
A simple blood test reveals a sugar pattern that spots inflammatory bowel disease early and shows how the illness quietly ages the body.
Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo
Guselkumab shows promise for ulcerative colitis in this early phase 3 trial.
This phase 3 randomized trial evaluated guselkumab in adults with moderately to severely active ulcerative colitis who had inadequate respon…
Patients with ulcerative colitis who failed other treatments achieved remission in a new trial using subcutaneous guselkumab injections.
Meta-analysis finds increased VTE risk in pediatric IBD, especially ulcerative colitis
Kids with Bowel Disease Face a Hidden Blood Clot Risk Adults Miss
A systematic review and meta-analysis of over 100,000 children and teenagers with IBD found a significantly increased risk of venous thrombo…
Children with Crohn's or ulcerative colitis face nearly seven times the blood clot risk of healthy kids, yet prevention guidelines for teens…
Single-cell sequencing reveals T cell clonal patterns in healthy donors and ulcerative colitis patients.
T Cells Move Freely in Colon, Not Just in Blood
This observational study analyzed 333,088 T cells from healthy donors and ulcerative colitis (UC) patients using single-cell T cell receptor…
T cells in the colon travel freely across the gut, not just in the blood, reshaping how we understand immune health in conditions like ulcer…
Meta-analysis of over 13 million births shows no association between Cesarean section and inflammatory bowel disease risk.
Does having a C-section raise your child's risk of inflammatory bowel disease?
This systematic review and meta-analysis evaluated the association between mode of delivery and risk of inflammatory bowel disease (IBD) in …
A review of over 13 million births found no link between C-sections and inflammatory bowel disease, easing concerns for parents.
PRO and Serum Biomarker Models Predict Endoscopic Activity in Ulcerative Colitis
Count Your Stools to Spot Flare-Ups Early
A retrospective multicenter cohort study of 297 UC patients developed models using patient-reported outcomes (stool frequency, rectal bleedi…
Counting your daily stools and bleeding can accurately spot ulcerative colitis flare-ups without needing an invasive colonoscopy.
Vedolizumab plus curcumin improves remission in moderate-to-severe ulcerative colitis versus vedolizumab alone.
Could adding curcumin to your current ulcerative colitis treatment help you reach remission faster?
This multicenter, double-blind randomized controlled trial enrolled 159 patients with moderate-to-severe ulcerative colitis. The study compa…
Adding curcumin to ulcerative colitis treatment helped more patients reach symptom remission faster than using standard drugs alone.
Single-cell and spatial technologies reveal UC pathogenesis insights but face sample size and phenotype heterogeneity limits.
New tech maps ulcerative colitis cells, but small study groups limit what we know for sure yet.
This systematic review evaluated single cell RNA sequencing, spatial transcriptomic, and proteomic technologies in adult ulcerative colitis …
New technology maps exactly which cells drive ulcerative colitis inflammation, helping explain why some patients respond to medicine while o…
Over 100 agents in development for moderate to severe ulcerative colitis, with early remission data for one class.
Many new ulcerative colitis drugs are in development, with early trial results for one type
A review describes a pipeline of over 100 investigational agents for moderate to severe ulcerative colitis. In early trials, tumor necrosis …
New ulcerative colitis drugs show over 25% remission in early trials, offering hope for the 20% of patients hospitalized within five years o…